ASHP – författare
Visar alla böcker från författaren ASHP. Handla med fri frakt och snabb leverans.
5 produkter
5 produkter
Inbunden, Engelska, 2022
5 494 kr
Skickas inom 5-8 vardagar
For more than 40 years ASHP has published the most trusted resource for injectable drug information. Our new ASHP® Injectable Drug Information now delivers the same high-quality content that you can expect from ASHP with even more of the information you need to make decisive patient care decisions.The 2023 edition of the industry's go-to guide is newly updated with the latest information, the full list of the AHFS® Pharmacologic-Therapeutic Classification© system, multiple new monographs, and nearly 200 new references for a total of over 24,000 total compatibility pairs.ASHP® Injectable Drug Information™ 2023 features more than 400 monographs, including:BrexanoloneCefiderocol sulfate tosylateOritavancinOliceridine fumarateRemdesivirRemimazolam besylateSildenafil citrate
Häftad, Engelska, 2022
4 920 kr
Skickas inom 5-8 vardagar
AHFS Drug Information® 2022 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.Updates in the new edition:The latest information on COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH).Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO).Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation.Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade.Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program.Expanded content on off-label uses, real-world data, and long-term clinical data.Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC).Addition of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021.
Häftad, Engelska, 2024
1 925 kr
Skickas inom 5-8 vardagar
Pediatric Injectable Drugs: The Teddy Bear Book is one of ASHP's most recognized and trusted resources dedicated to providing guidance on the use of injectable medications in children. For more than 20 years, pharmacists, physicians, nurses, and other health professionals have relied on The Teddy Bear Book to provide the most comprehensive research-based information on administering injectable medications to children.The Teddy Bear Book is the only reference of its kind that focuses on the unique issues that healthcare professionals face when using injectable medications in children, such as limited fluid volumes, maximum concentrations, and rates of administration.The 12th edition features more than 4,800 references for 273 updated monographs (including 7 monographs that are new to this edition) that, like previous editions, cover the following areas:Medication error potentialInfusion-related cautionsDosages and dose adjustment in organ dysfunctionAdditives and suitable diluentsMaximum concentrationsPreparation and deliveryBolus, intermittent, and continuous IV administrationOther routes of administrationNew monographs include:Cysteine Cytomegalovirus immunoglobulinDalbavancin DifibrotideFerric derisomaltoseFerrumoxytolVaricella zoster immune globulinNew features added to all monographs:Expanded monograph layoutPronunciationsEnhanced safety information including ASHP’s Standardize 4 Safety concentration standards, and The KIDs ListAHFS® Pharmacologic-Therapeutic Classification© specific category identification
Häftad, Engelska, 2024
5 480 kr
Skickas inom 5-8 vardagar
AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.Updates in the new edition:Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines.Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments.Contemporary topics such as new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more.Expanded content on new and emerging gene therapies.Updates to a variety of vaccine monographs including the pneumococcal, rabies, and respiratory syncytial virus vaccinesExpanded content on off-label uses and long-term clinical data,MedWatch alerts, Standardize4Safety information, REMS data, and focused FDA updates for various medications.New content on over 175 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 190 medications.
Häftad, Engelska, 2026
5 480 kr
Skickas inom 5-8 vardagar
AHFS Drug Information® 2026 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.Updates in the new edition:Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelinesExpanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustmentsContemporary topics such as biosimilars, novel orphan drugs, and updated vaccine guidance based on recommendations from the CDC’s Advisory Committee on Immunization Practices (ACIP) and other authoritative organizationsEssential drug information content for patient safety including FDA Medwatch alerts, Standardize4Safety concentrations for IV and oral liquid medications, ISMP recommendations, REMS data, BEERS criteria, boxed warnings, and focused updates based on FDA safety findingsPharmacogenomic considerations in drug dosing and selectionExpanded content on new and emerging gene and cellular therapiesClass-wide revisions to standard and established therapies for common disease states including hypertension and diabetesExpanded content on off-label uses, real world data, and long-term clinical dataNew content on new molecular entities (NMEs) and biologic approvalsNew oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee